Infectious risks associated with the transfusion of blood components and pathogen inactivation in Japan

International Journal of Hematology

Volumn 80, Issue 4, 2004, Pages 306-310

  Satake, Masahiro ^a  

^a JAPANESE RED CROSS SOCIETY   (Japan)

Author keywords

NAT; Pathogen inactivation; Residual risk; Transfusion

Indexed keywords

REAGENT;

BACILLUS CEREUS; BACTERIAL INFECTION; BLOOD DONOR; BLOOD TRANSFUSION; CORYNEBACTERIUM; CYTOMEGALOVIRUS; EPSTEIN BARR VIRUS; ERYTHROCYTE TRANSFUSION; HEPATITIS A VIRUS; HEPATITIS B; HEPATITIS C; HEPATITIS E VIRUS; HEPATITIS G VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS 1; INFECTION RISK; JAPAN; NUCLEIC ACID AMPLIFICATION; PARVOVIRUS; PROPIONIBACTERIUM ACNES; REVIEW; SCREENING TEST; SEPSIS; SEPTICEMIA; STAPHYLOCOCCUS; STREPTOCOCCUS PNEUMONIAE; THROMBOCYTE TRANSFUSION; VIRUS CARRIER; VIRUS GENOME; VIRUS INACTIVATION; VIRUS INFECTION; VIRUS LOAD; VIRUS TRANSMISSION; WEST NILE FLAVIVIRUS; YERSINIA ENTEROCOLITICA;

BACTERIAL INFECTIONS; BLOOD TRANSFUSION; BLOOD-BORNE PATHOGENS; HUMANS; INCIDENCE; JAPAN; RISK FACTORS; VIRUS DISEASES;

EID: 9444297964     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.04118     Document Type: Review

References (17)

1. Otake K, Nishioka K. Nucleic acid amplification testing of hepatitis B virus. Lancet. 2000;355:1460.
2. Mine H, Emura H, Miyamoto M, et al. High throughput screening of 16 million serologically negative blood donors for hepatitis B virus, hepatitis C virus and human immunodeficiency virus type-1 by nucleic acid amplification testing with specific and sensitive multiplex reagent in Japan. J Virol Methods. 2003;112:145-151.
3. AuBuchon JP. Pathogen inactivation in cellular blood components: clinical trials and implications of introduction to transfusion medicine. Vox Sang. 2002;83(suppl 1):271-275.
4. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood. 2004;104:1534-1541.
5. Atance R, Pereira A, Ramirez B. Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion. 2001;41:1548-1552.
6. Satake M. Residual risk of transfusion-transmitted diseases in Japan and pathogen inactivation. Vox Sang. 2002;83(suppl 1):277-279.
7. Muller-Breitkreutz K. Results of viral marker screening of unpaid blood donations and probability of window period donations in 1997. Vox Sang. 2000;78:149-157.
8. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections: the Retrovirus Epidemiology Donor Study. N Engl J Med. 1996;334:1685-1690.
9. Matsumoto C, Tadokoro K, Fujimura K, Hirakawa S, Mitsunaga S, Juji T. Analysis of HBV infection after blood transfusion in Japan through investigation of a comprehensive donor specimen repository. Transfusion. 2001;41:878-884.
10. Matsubayashi K, Nagaoka Y, Sakata H, et al. Transfusion-transmitted hepatitis E caused by apparently indigenous hepatitis E virus strain in Hokkaido, Japan. Transfusion. 2004;44:934-940.
11. Wendel S, Fontao-Wendel R, Germane S, Morato LE, Lazar A, Sakashita A. Screening of bacterial contamination in a routine scale for blood components production in a Brazilian blood bank. Vox Sang. 2000;78(suppl 1):376.
12. Mohr H, Knuver-Hopf J, Gravemann U, Redecker-Klein A, Muller TH. West Nile virus in plasma is highly sensitive to methylene blue-light treatment. Transfusion. 2004;44:886-890.
13. Mather T, Takeda T, Tassello J, et al. West Nile virus in blood: stability, distribution, and susceptibility to PEN110 inactivation. Transfusion. 2003;43:1029-1037.
14. Grass JA, Wafa T, Reames A, et al. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood. 1999;93:3140-3147.
15. Corash L, Lin L. Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease. Bone Marrow Transplant. 2004;33:1-7.
16. Ciaravino V, McCullough T, Dayan AD. Pharmacokinetic and toxicology assessment of INTERCEPT (s-59 and UVA treated) platelets. Hum Exp Toxicol. 2001;20:533-550.
17. Engelfriet CP, Reesink HW, Klein HG, et al. The future use of pathogen-inactivated platelet concentrates. Vox Sang. 2003;85:54-66.